According to the announcement from SIPAI HEALTH (00314), on April 22, 2026, SIPAI Investment (a wholly-owned subsidiary of the company) (as the seller) entered into a share transfer agreement with DSL (as the buyer). Accordingly, SIPAI Investment conditionally agreed to sell all of its equity in the target company SIPAI Zhihe Technology (Guangzhou) Co., Ltd. (a wholly-owned subsidiary of the company) for a total consideration of RMB 51.73 million.

As part of the sale, the company will also transfer its equity in two subsidiaries, Siwei Te and Beijing Renbo, to the target company, which will also constitute part of the target group to be sold by the company. Upon completion of the sale, the group will no longer hold any interests in the target company, and the target company will no longer be a subsidiary of the group, with its assets and liabilities no longer included in the group's consolidated financial statements. DSL will acquire 100% equity of the target subsidiary and the target company.

The company will periodically conduct strategic reviews of the group's assets to enhance shareholder value. Since 2024, the group has prioritized commercial health insurance and health management businesses for development. With strong industry trends and policy support, these business segments demonstrate robust growth momentum and significantly higher gross margins compared to specialty pharmacy operations. Considering the current market conditions of the pharmacy industry and the operational performance of the target company and target subsidiary's pharmacy business, the board believes that the sale will allow the group to further focus on its core strategy, optimize resource allocation, strengthen financial support for its core business, enhance the overall gross margin of the group, and accelerate the achievement of the group's overall profit targets